Mednet Logo
SpecialtiesNeurology
Neurology

Neurology

Expert perspectives on neurological conditions, stroke management, movement disorders, and neuromuscular disease.

Recent Discussions

When do you start anticoagulation in patients with endocarditis and evidence of mycotic aneursym?

1
3 Answers

Mednet Member
Mednet Member
Neurology · Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

True estimates of the risk of anticoagulation in endocarditis is hard to come by, since anticoagulation is not common in practice and likely the risk is dynamic and decreases with antibiotic treatment. If one considers thrombolysis as a guide, the presence of endocarditis appears to increase the ris...

How does lack of success of rituximab treatment affect your decision to trial anti-CD19 therapies like inebilizumab?

2 Answers

Mednet Member
Mednet Member
Neurology · Northwestern Medicine

I strongly believe that deeper and broader CD19 theraphy such as inebilizumab, works on a key different target: offering better disease control due to its broader B-cell targeting, as in CD19, plasmablasts, than rituximab, which targets CD20 (mature B cells), leading to more broad b cell depletion,...

How do you differentiate between HIV associated neurocognitive disease (HAND) and other causes of neurocognitive impairment?

1 Answers

Mednet Member
Mednet Member
Neurology · Unc Institute For Global Health And Infectious Diseases

This is a great question. In the era of test and treat, where many people with HIV have never had significant immunocompromise, cognitive impairment due to HIV itself is now relatively rare. On the other hand, people with HIV experience conditions of aging about 10 years earlier than people without ...

What are the best practices for centers interested in providing anti-amyloid therapies for early Alzheimer's to ensure treatment delivery success?

3 Answers

Mednet Member
Mednet Member
Neurology · Mount Sinai

I would use the same criteria for AAA treatment as those required for entering AAA clinical trials. Overall, our center has not had difficulty with ensuring that patients have timely MRIs before treatments. I enlist caregivers and patients to remind me when they are scheduled for their next infusion...

When do you consider hemispherectomy for patients with Rasmussen encephalitis with stable epilepsy and preserved function of the affected half of body?

1
1 Answers

Mednet Member
Mednet Member
Neurosurgery · Ucla Neurosurgery Residency Program

Depends on several factors. First, how debilitating are the seizures? If the person cannot function, like going to school for children or adult activities, then surgery to stop the seizures should be considered. Also, age is a factor. Children under the age of 5 years should be considered to make us...

What do you do for a patient with Parkinson's Disease and orthostatic hypotension who has failed midodrine, fludrocortisone, droxidopa, pyridostigmine, and atomoxetine?

1
2 Answers

Mednet Member
Mednet Member
Neurology · NewYork-Presbyterian Columbia University Irving Medical Center

I would not recommend using amantadine in this situation as it is known to worsen orthostatic hypotension (Perez-Lloret et al., PMID 22336566). This is a tricky situation, and if the patient has failed all of these medications, I would consider an alternate diagnosis, specifically MSA, especially if...

Which clinical or imaging features of cerebral amyloid angiopathy aid in predicting future risk of intracerebral hemorrhage?

1
2 Answers

Mednet Member
Mednet Member
Neurology · University of Maryland

Hemorrhagic imaging features of cerebral amyloid angiopathy can help understand the future risk of intracerebral hemorrhage (ICH). Observational studies have found that patients with cortical microbleeds without lobar hemorrhage have an ~5% risk of future ICH. In those with prior lobar ICH, this ris...

What would prompt discontinuing treatment versus switching or sequencing treatment in patients treated with an anti-amyloid therapy for Alzheimer's?

4 Answers

Mednet Member
Mednet Member
Neurology · Mayo Clinic

To be sure, there is virtually no evidence of outcomes on switching from one antibody to another. If treatment discontinuation occurred due to ARIA, I would strongly discourage rechallenge with another agent. There is no rationale for discontinuing lecanemab or donanemab for lack of efficacy on clin...

When do you recommend neuropsychiatric testing in patients with post-concussive syndrome?

4
4 Answers

Mednet Member
Mednet Member
Neurology · Hartford HealthCare

I typically ask the patient what scenarios they experience cognitive issues. The various examples they provide usually relate to difficulty following conversations, forgetfulness within their working memory, and concentration/focus. In the post-concussion patient, they typically have developed adjus...

How are you using CYP2C19 genotyping for determining dual antiplatelet therapy for stroke?

1
3 Answers

Mednet Member
Mednet Member
Neurology · HCA Houston Healthcare

In my practice, P2Y12 assays are the primary tool I rely on for guiding dual antiplatelet decisions. They are more widely available across clinical settings, whereas CYP2C19 genotyping requires infrastructure that is not always accessible outside of large academic and tertiary centers. CYP2C19 ident...